Vanlandingham B D, Maus T L, Brubaker R F
Mayo Medical School, Rochester, Minnesota, USA.
Ophthalmology. 1998 Aug;105(8):1537-40. doi: 10.1016/S0161-6420(98)98043-5.
The purpose of the study was to measure the effect of the topical carbonic anhydrase inhibitor, 2% dorzolamide hydrochloride, on the rate of aqueous humor flow in sleeping humans.
A randomized, double-masked, placebo-controlled study.
Twenty-five normal human subjects.
Topical instillation of 2% dorzolamide hydrochloride versus topical placebo.
Rate of aqueous humor flow in sleeping humans and intraocular pressure immediately after awakening from sleep.
The rate of flow in sleeping subjects at night (12 AM to 6 AM) was 1.28 +/- 0.30 microliters/min (mean +/- standard deviation; n = 25) in placebo-treated eyes, whereas the nighttime flow in dorzolamide-treated eyes was 1.17 +/- 0.38 microliters/min (P = < 0.001), resulting in a nighttime reduction of 9% (P = 0.032). In contrast, the daytime (8 AM to 4 PM) rate of flow in ambulatory subjects was 2.97 +/- 0.64 microliters/min in placebo-treated eyes and 2.60 +/- 0.63 microliters/min (P = 0.032) in dorzolamide-treated eyes, resulting in a daytime reduction of 13% (P = < 0.001).
Topically administered dorzolamide hydrochloride is effective for reducing the rate of aqueous humor flow in normal human eyes during the day and at night during sleep. The efficacy of dorzolamide at these two times is approximately half that of systematically administered acetazolamide.
本研究旨在测量局部应用碳酸酐酶抑制剂2%盐酸多佐胺对睡眠状态下人体房水生成速率的影响。
一项随机、双盲、安慰剂对照研究。
25名正常人类受试者。
局部滴注2%盐酸多佐胺与局部应用安慰剂。
睡眠状态下人体房水生成速率以及从睡眠中醒来后即刻的眼压。
在安慰剂治疗组眼中，睡眠受试者夜间（凌晨12点至早上6点）的房水生成速率为1.28±0.30微升/分钟（平均值±标准差；n = 25），而在多佐胺治疗组眼中，夜间房水生成速率为1.17±0.38微升/分钟（P =<0.001），导致夜间房水生成速率降低9%（P = 0.032）。相比之下，在日间（上午8点至下午4点）活动受试者中，安慰剂治疗组眼中的房水生成速率为2.97±0.64微升/分钟，多佐胺治疗组眼中为2.60±0.63微升/分钟（P = 0.032），导致日间房水生成速率降低13%（P =<0.001）。
局部应用盐酸多佐胺在白天和夜间睡眠期间均可有效降低正常人眼房水生成速率。多佐胺在这两个时段的疗效约为系统应用乙酰唑胺疗效的一半。
